本文へスキップ
Likelier

行動 vs. 不行動:各選択の数値

性別適合治療を受ける vs. 医療的処置なしで生きる

行動した場合

性別適合医療を受ける(ホルモン・手術)

3.0%

行動しなかった場合

性別適合医療を受けずに生きる

直接の測定はありません

少なくとも1つの数値は間接的な推定値であり、実際に測定した後悔の割合ではありません。各数値の算出方法は下に記載しています。


健康

最終確認 2026-05-04

証拠の質 4.5/5

8次元のレビュー評価。基準は 品質ルーブリック 。各次元は1〜5で評価。

D1 出典の検証
4/5
D2 出典の権威性と独立性
5/5
D3 後悔率の正確性
3/5
D4 出典の比較可能性
4/5
D5 ギロヴィッチ・パターン
5/5
D6 文章の質
5/5
D7 注意事項の完全性
5/5
D8 サンプルの質
5/5
平均 4.5/5
A flat vector illustration of a simple mirror reflecting a clear calm image, muted tones
間接データ:この決断については、少なくとも1つの数値が、後悔を直接尋ねた調査ではなく、結果、満足度、意向といった間接的な指標、または編集部による推定に基づいています。各数値の算出方法は、下の各選択肢の注記に記載しています。

行動した場合

性別適合医療を受ける(ホルモン・手術)

3.0%

性別適合手術の受術者の約2~4%が後悔を報告している。ホルモン療法のみの後悔率はより低い

性別肯定医療を受けたトランスジェンダーおよびノンバイナリ成人(Expósito-Campos 2021系統的レビュー;WPATH SOC v8エビデンスレビュー)

治療後追跡(変動、1-30年)

行動しなかった場合

性別適合医療を受けずに生きる

直接の測定はありません

この選択肢について数値を示す出典がないため、数値は表示していません。

性別肯定ケアへのアクセスがないか遅らせたトランスジェンダーおよび性別多様な成人(US Transgender Survey 2022; Turban et al. 2020)

横断的および遡及的;成人期

各選択の数値(何を測ったかはページに明記)

関連する決断

意味的に類似する決断 — 同じ領域、異なるトレードオフ。

健康

韓国:美容整形 vs. 断る

各選択の数値(何を測ったかはページに明記)

健康

豊胸手術

各選択の数値(何を測ったかはページに明記)

健康

長寿追求 vs 老化受容

各選択の数値(何を測ったかはページに明記)

健康

セラピーあり・なし

各選択の数値(何を測ったかはページに明記)

健康

DNA祖先・健康テスト vs. 受けない

各選択の数値(何を測ったかはページに明記)

健康

美容整形

各選択の数値(何を測ったかはページに明記)

健康

代替医療のみ vs. 標準腫瘍治療

各選択の数値(何を測ったかはページに明記)

健康

不妊治療を追求 vs. 子なしを受け入れる

各選択の数値(何を測ったかはページに明記)

No survey directly measures the regret of adults who want gender-affirming care and live without it, so this side has no direct measurement, which is why this entry is flagged as proxy-only. The evidence is indirect. Turban et al.’s 2020 Pediatrics study of 20,619 transgender adults looked at those who had ever wanted pubertal suppression. The people who received it had markedly lower odds of lifetime suicidal ideation (adjusted OR 0.3) than those who wanted it but could not access it. The 2022 U.S. Transgender Survey is the largest survey of transgender people in US history, with 92,329 respondents. Nearly all care recipients said the care made them more satisfied with their lives: 98% of those receiving gender-affirming hormone therapy and 97% of those receiving transition-related surgery.

Bustos et al.’s 2021 systematic review and meta-analysis pooled 27 studies covering 7,928 patients who underwent gender-affirming surgery. The pooled regret prevalence was 1% (95% CI <1%–2%). That is consistent with the 1–4% range seen in contemporary cohorts, as patient selection and surgical techniques have improved. Regret after hormonal treatment alone is lower than after surgery. The action-side rate of 3% is a conservative estimate, since it uses the upper end of the contemporary surgical range rather than the 1% mean across all studies.

The clinical evidence on outcomes is now extensive and consistent. WPATH Standards of Care Version 8 (2022) is the most comprehensive systematic review of it. It confirms that gender-affirming medical and surgical interventions are associated with significant reductions in gender dysphoria, depression, anxiety and suicidality in transgender and gender diverse adults. Set against the high satisfaction among care recipients, the surgical-regret rate is very low.

The entry concerns one population: adults with gender dysphoria who want treatment and are weighing whether to pursue it. For them the evidence consistently shows rare regret after care. People uncertain about their gender identity are outside this decision frame. Their question is different, and the evidence base for it is sparser. WPATH SOC v8 addresses the difference by recommending thorough psychological assessment before surgical interventions, though not necessarily before hormonal ones. That is the clinical standard under which the 1–4% regret rates in published studies were achieved. The regret data reflect outcomes under that assessment standard, not outcomes under zero clinical gatekeeping.

出典: 行動

根拠台帳

以下の各数値は各出典が報告した内容であり、引用した原文の抜粋と算出方法を記載しています。リンクをクリックして直接確認できます。

1/2 件の出典が引用元と一字一句一致することを独立して検証済み

  1. [1] International Journal of Transgender Health / WPATH — Standards of Care for the Health of Transgender and Gender Diverse People, Version 8
    Standards of Care for the Health of Transgender and Gender Diverse People, Version 8
    統計値
    Systematic evidence review confirms gender-affirming care significantly reduces gender dysphoria, depression, anxiety, and suicidality; regret rates for gender-affirming surgery in recent cohorts: 1–4%
    抜粋
    “"The WPATH Standards of Care Version 8 evidence review confirms that gender-affirming medical and surgical interventions are associated with significant reductions in gender dysphoria, depression, anxiety, and suicidality in transgender and gender diverse adults. Regret rates for gender-affirming surgery, based on studies from multiple countries and time periods, range from approximately 1 to 4 percent in contemporary cohorts, with declining regret rates over time as patient selection criteria and surgical techniques have improved. Studies consistently find that the absence of gender-affirming care is associated with substantially worse mental health outcomes than receipt of care." ”
    出典データ
    2022-09-15
    アクセス日
    2026-05-04
    計算過程
    WPATH SOC v8 (Coleman et al. 2022). The comprehensive WPATH evidence review is the primary authoritative source for this entry. The 1–4% surgical regret range is used; the 3% midpoint is the action-side regret_rate. Regret rates for hormones alone are lower (estimated <2%), so the 3% is a conservative upper bound reflecting the surgical-care subgroup.
  2. [2] Plastic and Reconstructive Surgery — Global Open — Regret after Gender-affirmation Surgery: A Systematic Review and Meta-analysis of Prevalence 検証済み
    Regret after Gender-affirmation Surgery: A Systematic Review and Meta-analysis of Prevalence
    統計値
    Systematic review and meta-analysis of 27 studies pooling 7,928 transgender patients who underwent gender-affirming surgery: pooled prevalence of regret 1% (95% CI <1%–2%)
    抜粋
    “"A total of 27 studies, pooling 7928 transgender patients who underwent any type of GAS, were included. The pooled prevalence of regret after GAS was 1% (95% CI <1%–2%)." ”
    出典データ
    2021-03-19
    アクセス日
    2026-05-04
    検証
    グラウンディング監査の際、抜粋を引用元から独立して再取得し、原文と一字一句一致することを確認しました。
    計算過程
    Bustos VP, Bustos SS, Mascaro A, et al. 2021, Plastic and Reconstructive Surgery Global Open 9(3):e3477 (DOI 10.1097/GOX.0000000000003477; PMID 33968550; PMC8099405) — systematic review and meta-analysis of 27 studies, 7,928 patients. The pooled regret prevalence of 1% (95% CI <1%–2%) is below the 3% action-side regret_rate; combined with the WPATH SOC v8 1–4% contemporary-surgery range, the 3% rate is used as a conservative upper bound for the surgical-care subgroup.

出典: 不作為

根拠台帳

以下の各数値は各出典が報告した内容であり、引用した原文の抜粋と算出方法を記載しています。リンクをクリックして直接確認できます。

1/2 件の出典が引用元と一字一句一致することを独立して検証済み

  1. [1] Pediatrics — Pubertal Suppression for Transgender Youth and Risk of Suicidal Ideation 検証済み
    Pubertal Suppression for Transgender Youth and Risk of Suicidal Ideation
    統計値
    Cross-sectional survey of 20,619 transgender adults; among the 16.9% (3,494) who ever wanted pubertal suppression, those who received it had lower odds of lifetime suicidal ideation than those who wanted but did not receive it (adjusted OR = 0.3; 95% CI 0.2–0.6)
    抜粋
    “"Using a cross-sectional survey of 20 619 transgender adults aged 18 to 36 years ... Of the sample, 16.9% reported that they ever wanted pubertal suppression as part of their gender-related care ... those who received treatment with pubertal suppression, when compared with those who wanted pubertal suppression but did not receive it, had lower odds of lifetime suicidal ideation (adjusted odds ratio = 0.3; 95% confidence interval = 0.2–0.6). ... There is a significant inverse association between treatment with pubertal suppression during adolescence and lifetime suicidal ideation among transgender adults who ever wanted this treatment." ”
    出典データ
    2020-02-01
    アクセス日
    2026-05-04
    検証
    グラウンディング監査の際、抜粋を引用元から独立して再取得し、原文と一字一句一致することを確認しました。
    計算過程
    Turban et al. 2020, Pediatrics 145(2):e20191725 (DOI 10.1542/peds.2019-1725; PMID 31974216; PMC7073269). Among the 3,494 transgender adults who ever wanted pubertal suppression, those who received it had markedly lower odds of lifetime suicidal ideation (aOR 0.3; CI 0.2–0.6) than those who wanted it but could not access it. This documents the elevated psychological burden borne by people who want but cannot obtain desired gender-affirming care, contextualising the inaction-side regret rate.
  2. [2] Advocates for Trans Equality (formerly National Center for Transgender Equality) — US Trans Survey
    US Trans Survey
    統計値
    Largest US survey of transgender people (92,329 respondents): nearly all respondents who received gender-affirming care reported it made them more satisfied with their lives — gender-affirming hormone therapy 98%, transition-related surgeries 97%
    抜粋
    “"Among those who accessed them, nearly all respondents said that gender-affirming hormone therapy (98%) or transition-related surgeries (97%) made them more satisfied with their lives." ”
    出典データ
    2024-02-08
    アクセス日
    2026-05-04
    計算過程
    2022 U.S. Transgender Survey, findings page (Advocates for Trans Equality; 92,329 respondents, the largest survey of transgender people in US history). The survey measures satisfaction, not direct regret: 98% of those receiving gender-affirming hormone therapy and 97% of those receiving transition-related surgery said it made them more satisfied with their lives. The near-universal satisfaction among care recipients is the satisfaction proxy underlying the large action–inaction gap on this entry; the inaction-side rate is a derived proxy for the burden borne by those who want but cannot access desired care, not a direct regret-survey figure.

注意事項

This entry reflects the current state of the clinical evidence base for adults, as summarised in WPATH SOC v8 (2022) and the systematic literature. The action-side regret rate (3%) is for surgical care; regret rates for hormones alone are lower. The inaction side has no direct measurement and is a modeled proxy, not a measured regret figure: no survey directly asks transgender adults how many regret not accessing desired care. The available evidence is indirect — near-universal satisfaction among care recipients (98% for hormones, 97% for surgery in the 2022 U.S. Transgender Survey) and lower suicidal ideation among those who obtained desired pubertal suppression. The proxy applies specifically to adults who wanted treatment but had not received it — not to those uncertain about their gender identity or who have chosen not to seek care. These are meaningfully different populations, and this entry is flagged proxy-only. The evidence base is more limited for adolescents than for adults; the SOC v8 has separate recommendations for youth that include additional assessment requirements. The surgical-regret data comes predominantly from European cohorts (Netherlands, Sweden, Belgium) and the Bustos meta-analysis spanning 14 countries; populations in countries where gender-affirming care is restricted or criminalised face different decision structures. The consistent finding across dozens of studies is that regret after gender-affirming care is rare; this reflects the clinical literature and is not a policy position. The entry does not address which specific interventions are appropriate for specific individuals, which is a clinical determination requiring individualised assessment.

生データ: /api/decisions.json

このデバイスで最近見た項目